PAF1 and neoplasm: ,38 We investigated tumor growth and responses of ATOH1 CDX models to the SoC (cisplatin/etoposide) in vivo, adopting a modified version of preclinical response evaluation criteria in solid tumors (pRECIST) (STAR Methods); tumor growth data are transformed to progressive disease (PD1 and PD2), stable disease, and partial response, complete response, and maintained complete response.39